A Study Evaluating Longidaza^® Published in Urologia Journal: Combination Treatment Reduced the Risk of Chronic Prostatitis Recurrence Nearly Fourfold

Chronic prostatitis remains one of the most challenging urological conditions to treat: the disease frequently recurs even after antibacterial treatment and is often associated with impaired reproductive function. Results of a study conducted by Russian researchers and published in Urologia Journal^[1] demonstrate that targeting bacterial biofilms can significantly improve treatment outcomes and reduce the risk of disease recurrence by nearly fourfold.

Chronic prostatitis is among the most common urological disorders in men, affecting approximately 40% of patients^[2]. Bacterial infections are one of the key factors contributing to disease development; however, standard antibiotic treatment does not always achieve complete resolution of inflammation^[3]. The chronic course of prostatitis and its recurrent exacerbations are often associated with biofilms—specialized structures that protect bacteria from both antibiotics and the immune system. Biofilms may increase bacterial resistance to antibiotic treatment by as much as 1,000-fold^[4]. As a result, the pathological process may become chronic, leading to prostate fibrosis and impaired fertility^[5].

The randomized controlled study enrolled 98 patients with chronic bacterial prostatitis and infertility. Participants were divided into two groups: one received standard antibacterial treatment, while the other received antibiotics combined with Longidaza^® (bovhyaluronidase azoximer). The follow-up period lasted 12 months.

The study demonstrated that the addition of bovhyaluronidase azoximer significantly improved clinical outcomes. The recurrence rate at 6 months was 10.6% versus 40.8% in the standard treatment group, while at 12 months it was 38.3% versus 89.8%, respectively. Moreover, no cases of multiple recurrences during the one-year follow-up period were recorded in the combination treatment group, whereas they occurred in nearly half of the patients in the control group (49%).

In addition, treatment had a pronounced effect on inflammatory markers. Complete elimination of neutrophils in ejaculate was achieved in 41% of patients receiving combination treatment, compared with 7.2% in the control group, while complete eradication of bacterial colonies was observed in 41.7% versus 12.1% of patients, respectively.

According to the authors, these findings are especially important in the context of the global rise in antibiotic resistance. They suggest that incorporating therapeutic approaches aimed at disrupting bacterial biofilms may improve the effectiveness of existing treatment regimens and improve long-term outcomes in patients with chronic prostatitis.